Mechanisms of adverse effects during hemapheresis.
For over 20 years blood components have been collected from normal donors by automated hemapheresis. Cell separators have become increasingly sophisticated, and relatively pure component "concentrates" can be obtained quite safely. Cytapheresis donors are monitored carefully, and serious reactions are very rare. In contrast, therapeutic apheresis procedures may be technically demanding and frequently are performed on very sick patients. Large volumes of blood are rapidly removed from the patient, anticoagulated, and separated into components by the automated cell separator. The blood component containing the pathogenetic factor (e.g., plasma containing an antibody) is retained outside of the body, and the remaining components (e.g., red cells, white cells, and platelets) plus the replacement fluid are reinfused. Complications can occur in normal cytapheresis donors because of the technical challenges of the procedure (e.g., extracorporeal circuit to be filled, use of citrate anticoagulant, need for large bore intravascular access, and rapid blood flow rates). All of these factors apply also to therapeutic patients plus the additional requirement for replacement fluids, and the clinical features of the underlying illness for which each patient is being treated. Fortunately, even with therapeutic patients, most complications are of modest severity and are easily managed with only temporary slowing or interruption of the hemapheresis procedure.